biuro@scopefluidics.com
+48 22 376 21 14
About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact
biuro@scopefluidics.com
+48 22 376 21 14
About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact
biuro@scopefluidics.com
+48 22 376 21 14
RAPORT ESPI 17/2023|12-06-2023|Podsumowanie działań w ramach Scope Discovery
Previous Post
RAPORT ESPI 16/2023|02-06-2023|Dopuszczenie i wprowadzenie akcji Emitenta do obrotu giełdowego na rynku regulowanym prowadzonym przez GPW
Next Post
RAPORT ESPI 18/2023|28-06-2023|Zawiadomienie od akcjonariuszy
0
Shares
Related Posts
15.10.2026
Edocera develops device prototype and confirms its ability to detect signs of stroke
SCOPE FLUIDICS
0
30.09.2026
Scope Fluidics after the first half of 2026: strong cash position, IVDR certification and expanding cooperation with distributors
SCOPE FLUIDICS
0
28.09.2026
Hybolic signs PARP funding agreement to develop a system for measuring insulin and glucose concentrations
SCOPE FLUIDICS
0
